Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Vifor Licenses Isotechnika’s Lead Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Vifor Licenses Isotechnika’s Lead Drug

Partnership expands voclosporin for other indications

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isotechnika Pharma has signed a global development and commercialization license agreement with Vifor Pharma Ltd., granting Vifor an exclusive license for its lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications. The license is for the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong. Isotechnika is eligible to receive upfront and milestone payments, as well as royalties on commercial sales. Vifor will also purchase voclosporin capsules from Isotechnika. Financial details of the transaction were not disclosed.

“While the successful development of voclosporin for the prevention of kidney transplant rejection remains our primary focus, we believe the expansion of our platform beyond that indication via partnerships like this may help to unlock the drug’s full medical and commercial potential,” said Dr. Robert Foster, chief executive officer of Isotechnika. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics